drugset

drugset / Trial / NCT05136456

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

NCT05136456 ↗

Phase 2 Unknown 61 enrolled Reistone Biopharma Company Limited

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.

Timeline

Start: 2021-12-15
Primary completion: 2023-08-28
Completion: 2024-03-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	EDRALBRUTINIB	Small molecule	—	Oral

Indications